Stoke Therapeutics, Inc. $STOK Stake Decreased by Troluce Capital Advisors LLC

Troluce Capital Advisors LLC cut its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 24.0% during the second quarter, HoldingsChannel.com reports. The fund owned 496,416 shares of the company’s stock after selling 156,384 shares during the period. Stoke Therapeutics accounts for about 1.7% of Troluce Capital Advisors LLC’s holdings, making the stock its 6th largest holding. Troluce Capital Advisors LLC’s holdings in Stoke Therapeutics were worth $16,243,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of STOK. Dimensional Fund Advisors LP grew its position in shares of Stoke Therapeutics by 19.7% in the first quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after purchasing an additional 162,797 shares in the last quarter. Janus Henderson Group PLC lifted its position in Stoke Therapeutics by 11.2% during the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock worth $52,456,000 after buying an additional 161,848 shares in the last quarter. Candriam S.C.A. lifted its position in Stoke Therapeutics by 12.4% during the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock worth $16,346,000 after buying an additional 55,330 shares in the last quarter. Bank of America Corp DE boosted its stake in Stoke Therapeutics by 163.4% during the first quarter. Bank of America Corp DE now owns 543,095 shares of the company’s stock worth $17,683,000 after buying an additional 336,931 shares during the last quarter. Finally, EcoR1 Capital LLC acquired a new position in Stoke Therapeutics during the first quarter worth $3,256,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on STOK. Guggenheim reaffirmed a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Wedbush boosted their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price objective for the company. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Finally, The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $44.00 target price on the stock. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.25.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the transaction, the general counsel directly owned 21,225 shares in the company, valued at $679,836.75. This represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 5,545 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $30.67, for a total value of $170,065.15. Following the transaction, the insider owned 20,110 shares of the company’s stock, valued at approximately $616,773.70. This represents a 21.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 34,373 shares of company stock valued at $1,068,939 over the last quarter. 9.60% of the stock is owned by company insiders.

Stoke Therapeutics Trading Down 0.6%

Shares of NASDAQ:STOK opened at $29.81 on Friday. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -8.93 and a beta of 1.23. Stoke Therapeutics, Inc. has a 12-month low of $19.55 and a 12-month high of $40.22. The business has a 50-day moving average price of $31.17 and a 200 day moving average price of $32.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, equities research analysts predict that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.